Non-small Cell Lung Carcinoma
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-22EMA Authorised: Lumykras (sotorasib) — Amgen Europe B.V.
Lumykras (sotorasib) has been authorised by EMA for non-small cell lung carcinoma under conditional approval.
-
EMA approval · 2026-07-15EMA Authorised: Rozlytrek (Entrectinib) — Roche Registration GmbH
The EMA authorises Rozlytrek (entrectinib) for cancer, including non-small cell lung carcinoma, under conditional approval.
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
EMA approval · 2023-07-17EMA Authorised: Iressa (gefitinib) — AstraZeneca AB
Iressa (gefitinib) is authorised in the EU for non-small cell lung carcinoma (carcinoma, non-small-cell lung).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.